紅日藥業(300026.SZ)複方電解質注射液(Ⅱ)獲藥品註冊批件
格隆匯8月16日丨紅日藥業(300026.SZ)宣佈,公司於近日收到國家藥品監督管理局下發的藥品註冊批件(批件號:2019S00462、2019S00463)。其中複方電解質注射液(Ⅱ)250ml規格,藥品批准文號國藥準字H20193223,有效期至2024年8月1日;複方電解質注射液(Ⅱ)500ml規格藥品批准文號國藥準字H20193224,有效期至2024年8月1。
該品種獲批適應症為用於治療伴隨或預期出現酸中毒的等滲性脱水,補充細胞外液的丟失。目前公司已着手進行上市銷售前的準備工作,由於醫藥產品具有高科技、高風險、高附加值的特點,藥品投產後的未來市場銷售情況可能受到市場環境變化、招投標開展等因素影響,存在不確定性
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.